Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has now recruited more than half the patients for its Phase IIa trial of its drug candidate QGC001. This is four months ahead of the recruitment schedule set by the company.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/09/QGC_PR_QGC001-enrolment-50_20150908_EN2.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
